Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial Positive high-level results from a planned interim analysis of the MATTERHORN…
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved…
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus
Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus AbbVie (NYSE: ABBV) today announced the…
Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer
Insilico Medicine receives IND approval for novel AI-designed USP1 inhibitor for cancer Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical stage drug discovery company, announced that the U.S. Food…
U.S. FDA approves ABRYSVO™, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults
U.S. FDA approves ABRYSVO™, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA)…
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has…
Syneos Health Launches Medical Affairs Digital Amplifier
Syneos Health Launches Medical Affairs Digital Amplifier Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical Affairs Digital Amplifier, a program designed to…
New WHA resolution to accelerate efforts on food micronutrient fortification
New WHA resolution to accelerate efforts on food micronutrient fortification The delegates at the Seventy-sixth World Health Assembly adopted the resolution on accelerating efforts to prevent micronutrient deficiencies through safe…
76th World Health Assembly adopts first ever resolution on drowning prevention
76th World Health Assembly adopts first ever resolution on drowning prevention Today the 76th World Health Assembly adopted its first ever resolution on drowning prevention requesting governments and their partners, in…
New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer’s disease
New blood biomarker can predict if cognitively healthy elderly will develop Alzheimer’s disease Why do some people develop Alzheimer’s disease while others don’t? And, even more puzzlingly, why do many…
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel…
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development Catalent, the leader in enabling the development and supply of…